Country: China

INT Medical, operating as Shanghai INT Medical Instruments Co., Ltd., is a Chinese manufacturer focused on the research, development, production, and distribution of interventional medical devices. Established in 2006 and headquartered in Shanghai, with additional major production bases in Zhuhai (Guangdong) and Rizhao (Shandong), the company is publicly listed on the main board of the Hong Kong Stock Exchange under the stock code HK1501. INT Medical has steadily built a leading position in the Chinese cardiovascular interventional device sector. It ranks among the few domestic medical device enterprises with fully integrated industrial capabilities spanning proprietary mould development, in-house product research and development, equipment engineering, and independent sterilisation. Its comprehensive product portfolio is organised across seven main categories: cardiac intervention, neurovascular intervention, peripheral interventional implantation, orthopaedic interventional implantation, urological intervention, non-vascular intervention and other applications, along with medical standard parts. Signature offerings include sheath sets, hydrophilic and stiff guidewires, invasive blood pressure sensors, steerable sheaths, delivery catheters, micro guidewires, angiographic catheters, absorbable hemostatic gelatin, thoracic aortic stent systems, bone cement moulding kits, vertebral expansion pressure pumps, ureteral pyeloscopes, electronic endoscope image processors, negative pressure drainage devices, and radioactive drug infusion connection lines.

Backed by more than 2,000 employees, three major production bases, and 24 subsidiaries covering cardiovascular, peripheral vascular, neurovascular, cardiac electrophysiology, structural heart disease, and non-vascular business segments, INT Medical combines refined manufacturing techniques with rigorous quality control to deliver equipment that meets internationally recognised standards. As of December 31, 2025, the company has 120 domestically registered products, 43 CE-certified products, 26 FDA-certified products, 734 authorised patents, 237 patents pending, and 42 software copyrights. Its products carry widely respected certifications including ISO 13485, CE, and FDA, reflecting the company's strong commitment to safety, reliability, and consistent performance. INT Medical has also earned numerous recognitions, including the National Specialised and Innovative "Little Giant" title, National Intellectual Property Advantage Enterprise, Shanghai Enterprise Technology Centre, and Shanghai Patent Demonstration Enterprise, along with support from more than 70 government projects. Since 2024, the company has been selected in the S&P Global "Sustainability Yearbook (China Edition)" for two consecutive years.

With a distribution reach extending to more than 90 countries and regions worldwide, INT Medical serves hospitals, cardiovascular centres, interventional radiologists, and healthcare institutions of every scale. Guided by its core values of "Dedication, Selflessness, Innovation, and Efficiency" and its guiding philosophy that "Innovation Serves Health, Quality Builds Extraordinary," the company continues to strengthen its independent innovation capabilities and develop proprietary intellectual property. Aspiring to fulfil its vision of "becoming a world-renowned medical group led by technological innovation," INT Medical positions itself as a trusted Chinese partner for interventional medicine professionals seeking high-quality, technologically advanced, and clinically dependable interventional solutions on a truly worldwide scale.